Imaging in sarcoma

Journal of Nuclear Medicine

Volumn 52, Issue 12, 2011, Pages 1903-1913

  Eary, Janet F ^a   Conrad, Ernest U ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Diagnosis; PET; Sarcoma; Treatment response imaging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M;

BONE SCINTISCANNING; CANCER CLASSIFICATION; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TYPE; CELL VIABILITY; CLINICAL FEATURE; CLINICAL PRACTICE; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; MEDICAL DECISION MAKING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; RISK ASSESSMENT; SARCOMA; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR NECROSIS; TUMOR VOLUME;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SARCOMA; TREATMENT OUTCOME;

EID: 83755168331     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.092999     Document Type: Review

References (64)

1. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14:1679-1689. (Pubitemid 26134227)
2. Gadgeel SM, Harlan LC, Zeruto CA, Osswald M, Schwartz AG. Patterns of care in a population-based sample of soft tissue sarcoma patients in the United States. Cancer. 2009;115:2744-2754.
3. Salas S, Stoeckle E, Collin F, et al. Superficial soft tissue sarcomas (S-STS): a study of 367 patients from the French Sarcoma Group (FSG) database. Eur J Cancer. 2009;45:2091-2102.
4. Engellau J, Bendahl PO, Persson A, et al. Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol. 2005;36:994-1002. (Pubitemid 41253386)
5. Nair SG, Amadio CH, Scarlato M, Forman DA. Frequency of histopathologic types of soft tissue sarcoma (STS) reported from a large community-based hospital over a 20 year period [abstract]. J Clin Oncol. 2006;24(suppl):19507.
6. Eary JF. PET-CT and SPECT-CT of malignant bone tumors and PET and PET-CT in soft tissue sarcomas. In: von Schulthess GK, ed. Molecular Anatomic Imaging: PET-CT and SPECT-CT Integrated Modality Imaging. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:443-449, 456-467.
7. Coley HM, Verrill MW, Gregson SE, Odell DE, Fisher C, Judson IR. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur J Cancer. 2000;36:881-888. (Pubitemid 30214138)
8. Komdeur R, Plaat BE, Hoekstra HJ, et al. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer. 2001;91:1940-1948. (Pubitemid 32424122)
9. Komdeur R, Plaat BE, van der Graaf WT, et al. Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Eur J Cancer. 2003;39:909-916. (Pubitemid 36428622)
10. Komdeur R, Molenaar WM, Zwart N, Hoekstra HJ, van den Berg E, van der Graaf WT. Multidrug resistance proteins in primary and metastatic soft-tissue sarcomas: down-regulation of P-glycoprotein during metastatic progression. Anticancer Res. 2004;24:291-295. (Pubitemid 38279721)
11. Oda Y, Saito T, Tateishi N, et al. ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. Int J Cancer. 2005;114:854-862.
12. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer. 2003;3:685-694. (Pubitemid 37328823)
13. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91:1914-1926. (Pubitemid 32424119)
14. Deyrup AT, Weiss SW. Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world. Histopathology. 2006;48:42-50.
15. Wunder JS, Healey JH, Davis AM, Brennan MF. A comparison of staging systems for localized extremity soft tissue sarcoma. Cancer. 2000;88:2721-2730. (Pubitemid 30417932)
16. Spiessl B, Beahrs OH, Hermanek P, et al. eds. TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours. 3rd ed, 2nd rev. Berlin, Germany: Springer-Verlag; 1992.
17. Kim MS, Lee SY, Lee TR, et al. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol. 2009;20:955-960.
18. Antunes M, Bernardo J, Salete M, Prieto D, Eugénio L, Tavares P. Excision of pulmonary metastases of osteogenic sarcoma of the limbs. Eur J Cardiothorac Surg. 1999;15:592-596. (Pubitemid 29251752)
19. 18F-18 FDG PET/CT and bone marrow biopsy. Eur J Nucl Med Mol Imaging. 2008;35:1746.
20. Goto Y, Ihara K, Kawauchi S, Ohi R, Sasaki K, Kawai S. Clinical significance of thallium-201 scintigraphy in bone and soft tissue tumors. J Orthop Sci. 2002;7:304-312. (Pubitemid 34742353)
21. McCarville MB, Barton EH, Cameron JR, et al. The cause and clinical significance of central tumor photopenia on thallium scintigraphy of pediatric osteosarcoma of the extremity. AJR. 2007;188:572-578. (Pubitemid 46167761)
22. Eary JF, Conrad EU, Bruckner JD, et al. Quantitative [F-18] fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res. 1998;4:1215-1220. (Pubitemid 28213332)
23. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med. 1996;37:257-261. (Pubitemid 26150898)
24. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology. 1992;182:185-194.
25. Ioannidis JP, Lau J. 18-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med. 2003;44:717-724. (Pubitemid 39655205)
26. 18F-FDG uptake as a predictor of patient outcome. J Nucl Med. 2008;49:1973-1979.
27. Evilevitch V, Weber WA, Tap WD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2008;14:715-720. (Pubitemid 351231152)
28. Benz MR, Czernin J, Tap WD, et al. FDG-PET/CT imaging predicts histopathologic treatment responses after neoadjuvant therapy in adult primary bone sarcomas. Sarcoma. April 18, 2010 [Epub ahead of print].
29. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25:1760-1764. (Pubitemid 46797958)
30. Schuetze SM, Baker LH, Benjamin RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist. 2008;13(suppl 2):32-40.
31. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059-1066.
32. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785-2808. (Pubitemid 40525178)
33. Benz MR, Allen-Auerbach MS, Eilber FC, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008;49:1579-1584.
34. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46:983-995. (Pubitemid 43733514)
35. 18FDG PET. Methods Mol Med. 2005;111:417-440.
36. Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-171.
37. Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32:153-162. (Pubitemid 40248485)
38. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-2020.
39. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38(suppl 5):S60-S65.
40. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45:357-365. (Pubitemid 47618607)
41. 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17-21.
42. Jager PL, Gietma JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun. 2004;25:433-438. (Pubitemid 38591102)
43. McAuliffe JC, Hunt KK, Lazar AJ, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009;16:910-919.
44. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566-578. (Pubitemid 40613322)
45. Schuetze SM. Imaging and response in soft tissue sarcomas. Hematol Oncol Clin North Am. 2005;19:471-487. (Pubitemid 40797885)
46. Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol. 2006;18:369-373. (Pubitemid 44297249)
47. Hicks RJ. Functional imaging techniques for evaluation of sarcomas. Cancer Imaging. 2005;5:58-65.
48. Khamly KK, Hicks RJ, McArthur GA, Thomas DM. The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas. Expert Rev Mol Diagn. 2008;8:105-119.
49. Toner GC, Hicks RJ. PET for sarcomas other than gastrointestinal stromal tumors. Oncologist. 2008;13(suppl 2):22-26.
50. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005;103:339-348. (Pubitemid 40129294)
51. 18F] fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23:8828-8834.
52. Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999;40:1637-1643. (Pubitemid 29471153)
53. 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression. Clin Exp Metastasis. 2008;25:427-435.
54. 18F-FDG-PET. Ann Nucl Med. 2008;22:475-480.
55. Hawkins DS, Rajendran JG, Conrad EU III, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D- glucose positron emission tomography. Cancer. 2002;94:3277-3284. (Pubitemid 34670512)
56. Franzius C, Schober O. Assessment of therapy response by FDG PET in pediatric patients. Q J Nucl Med. 2003;47:41-45. (Pubitemid 36826760)
57. McCarville MB, Christie R, Daw NC, Spunt SL, Kaste SC. PET/CT in the evaluation of childhood sarcomas. AJR. 2005;184:1293-1304. (Pubitemid 43821916)
58. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49(suppl 2):129S-148S. (Pubitemid 351948041)
59. 18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695-704.
60. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82:699-757. (Pubitemid 44832019)
61. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res. 2005;11:7967-7985. (Pubitemid 41698738)
62. 18F-3′-fluoro- 3′-deoxy-L-thymidine. Clin Cancer Res. 2004;10:1685-1690.
63. 18F]fluorodeoxythymidine. Clin Cancer Res. 2008;14:2970-2977.
64. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J Nucl Med. 2007;48:367-372.